Fighting Antimicrobial Resistance 2018
DOI: 10.5599/obp.15.9
|View full text |Cite
|
Sign up to set email alerts
|

ighting antimicrobial resistance in ESKAPE pathogens

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
1
0
1

Year Published

2020
2020
2022
2022

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(2 citation statements)
references
References 36 publications
0
1
0
1
Order By: Relevance
“…Due to the high pressure exerted by antimicrobial resistance and the increasing prevalence of multiresistant bacteria, the development of new and beneficial treatments is required. Several treatments against multiresistant pathogens have been developed over time, including: new drugs, phage therapy (including derivates), antivirulence therapy, lysins, antibodies, probiotics, and immune stimulation [ 13 ]. The particular problem with antimicrobial treatment is the delivery method of the antimicrobial agents and avoiding the systemic uptake that increases the selection of resistant bacteria.…”
Section: Introductionmentioning
confidence: 99%
“…Due to the high pressure exerted by antimicrobial resistance and the increasing prevalence of multiresistant bacteria, the development of new and beneficial treatments is required. Several treatments against multiresistant pathogens have been developed over time, including: new drugs, phage therapy (including derivates), antivirulence therapy, lysins, antibodies, probiotics, and immune stimulation [ 13 ]. The particular problem with antimicrobial treatment is the delivery method of the antimicrobial agents and avoiding the systemic uptake that increases the selection of resistant bacteria.…”
Section: Introductionmentioning
confidence: 99%
“…Las infecciones causadas por este patógeno son habitualmente difíciles de tratar debido a la resistencia intrínseca a los antibióticos que se utilizan para su tratamiento [7]. Los antibióticos carbapenémicos son parte del arsenal terapéutico utilizado en el tratamiento de las infecciones causadas por ambos patógenos, pero el incremento progresivo de las infecciones por enterobacterias resistentes a cefalosporinas de tercera generación ha conllevado un incremento sustancial de su uso y ello, sumado a la rápida diseminación de los genes de resistencia entre distintos grupos bacterianos, ha favorecido la emergencia de resistencia a este grupo de antibióticos [8,9]. Generalmente, los factores de riesgo (FR) asociados a infecciones por microorganismos resistentes a un determinado grupo de antibióticos incluyen: características del huésped (comorbilidad), exposición previa a antibióticos, y realización de procedimientos invasivos [10].…”
Section: Introductionunclassified